Vertex Pharmaceuticals Appoints CFO Jonathan Poole, Effective Jan 1, 2027

What Happened

• Vertex Pharmaceuticals (VRTX) announced on an 8-K (filed Sept 1, 2026) that it appointed Jonathan Poole as Executive Vice President and Chief Financial Officer, effective January 1, 2027. Charles F. Wagner, Jr. will cease serving as CFO on that date but will remain Executive VP and Chief Operating Officer.
• Mr. Poole, 51, has been Senior Vice President, Finance at Vertex since March 2020 and previously served as CFO of Evelo Biosciences (2018–2020) and Genocea Biosciences (2014–2018). He holds a B.Sc. in Biological Sciences from Durham University and an MBA from London Business School.

Key Details

• Start date: January 1, 2027; appointment announced Aug 27, 2026 and reported on 8-K filed Sept 1, 2026.
• Compensation: base salary $750,000 and target annual bonus of 90% of base salary.
• Severance: if terminated without cause or if he leaves for “good reason,” he is entitled (subject to a release) to 100% of base salary plus target bonus for the year of termination, plus any earned unpaid prior-year bonus.
• Change-of-control protections: within 90 days before or 12 months after a change of control (or similar qualifying termination), he would receive 100% of base + target bonus, a pro-rated bonus for the year, payment of other earned cash incentives, full vesting of outstanding equity (performance criteria not yet certified deemed achieved at target), and up to 12 months of company-paid insurance premiums if COBRA is elected.

Why It Matters

• The company is naming an experienced finance executive to lead its finance function; this is a material leadership change for investors given the CFO’s role in financial strategy, reporting and investor communication.
• The disclosed compensation and robust change-of-control severance protections are important for shareholders to understand potential costs and incentives tied to the new CFO’s appointment.
• The filing notes no related-party transactions requiring disclosure under Item 404(a) and that the full employment and change-of-control agreements will be filed as exhibits in Vertex’s upcoming Form 10-Q for the quarter ended Sept 30, 2026.